{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:26:10Z","timestamp":1740162370157,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T00:00:00Z","timestamp":1668211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T00:00:00Z","timestamp":1668211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82100872"],"award-info":[{"award-number":["82100872"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"High-level Personnel Research Start-up Funding of Fujian medical university","award":["XRCZX2020003"],"award-info":[{"award-number":["XRCZX2020003"]}]},{"name":"Scientific Research Project of Fujian Education Department","award":["JAT190175"],"award-info":[{"award-number":["JAT190175"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s11096-022-01510-8","type":"journal-article","created":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T19:03:03Z","timestamp":1668279783000},"page":"154-162","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Direct-acting antiviral agent use and gastrointestinal safety in patients with chronic hepatitis C: a pharmacovigilance study based on FDA\u00a0Adverse Event Reporting System"],"prefix":"10.1007","volume":"45","author":[{"given":"Wenhuo","family":"Xie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linyao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianbin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5444-8084","authenticated-orcid":false,"given":"Yu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,12]]},"reference":[{"issue":"8","key":"1510_CR1","doi-asserted-by":"publisher","first-page":"102589","DOI":"10.1016\/j.autrev.2020.102589","volume":"19","author":"C Mazzaro","year":"2020","unstructured":"Mazzaro C, Dal Maso L, Mauro E, et al. Hepatitis C virus- related cryoglobulinemic vasculitis: a review of the role of the new direct antiviral agents (DAAs) therapy. Autoimmun Rev. 2020;19(8):102589.","journal-title":"Autoimmun Rev"},{"issue":"13","key":"1510_CR2","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1080\/14656566.2021.1921737","volume":"22","author":"C Stanciu","year":"2021","unstructured":"Stanciu C, Muzica CM, Girleanu I, et al. An update on direct antiviral agents for the treatment of hepatitis C. Expert Opin Pharmacother. 2021;22(13):1729\u201341.","journal-title":"Expert Opin Pharmacother"},{"issue":"10179","key":"1510_CR3","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","volume":"393","author":"F Carrat","year":"2019","unstructured":"Carrat F, Fontaine H, Dorival C, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet. 2019;393(10179):1453\u201364.","journal-title":"Lancet"},{"key":"1510_CR4","doi-asserted-by":"publisher","first-page":"e1017-e21","DOI":"10.1097\/MEG.0000000000002173","volume":"33","author":"K Hayes","year":"2021","unstructured":"Hayes K, Burkard T, Weiler S, et al. Global adverse events reported for direct-acting antiviral therapies for the treatment of hepatitis C: an analysis of the World Health Organization VigiBase. Eur J Gastroenterol Hepatol. 2021;33:e1017-e21.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"6","key":"1510_CR5","doi-asserted-by":"publisher","first-page":"e194765","DOI":"10.1001\/jamanetworkopen.2019.4765","volume":"2","author":"EA McGlynn","year":"2019","unstructured":"McGlynn EA, Adams JL, Kramer J, et al. Assessing the safety of direct-acting antiviral agents for hepatitis C. JAMA Netw Open. 2019;2(6):e194765.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"1510_CR6","doi-asserted-by":"publisher","first-page":"e1007100","DOI":"10.1371\/journal.pcbi.1007100","volume":"15","author":"M Ben Guebila","year":"2019","unstructured":"Ben Guebila M, Thiele I. Predicting gastrointestinal drug effects using contextualized metabolic models. PLoS Comput Biol. 2019;15(6):e1007100.","journal-title":"PLoS Comput Biol"},{"issue":"2","key":"1510_CR7","doi-asserted-by":"publisher","first-page":"84","DOI":"10.37765\/ajmc.2020.42397","volume":"26","author":"J Jung","year":"2020","unstructured":"Jung J, Du P, Feldman R, et al. Discontinuation of new hepatitis C drugs among medicare patients. Am J Manag Care. 2020;26(2):84\u20138.","journal-title":"Am J Manag Care"},{"issue":"2","key":"1510_CR8","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/hep.28995","volume":"66","author":"WF Balistreri","year":"2017","unstructured":"Balistreri WF, Murray KF, Rosenthal P, et al. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12\u201317 years old with hepatitis C virus genotype 1 infection. Hepatology. 2017;66(2):371\u201378.","journal-title":"Hepatology"},{"issue":"22","key":"1510_CR9","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","volume":"376","author":"M Bourli\u00e8re","year":"2017","unstructured":"Bourli\u00e8re M, Gordon SC, Flamm SL, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med. 2017;376(22):2134\u201346.","journal-title":"N Engl J Med"},{"issue":"7","key":"1510_CR10","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1111\/apt.16037","volume":"52","author":"G Indolfi","year":"2020","unstructured":"Indolfi G, Giometto S, Serranti D, et al. Systematic review with meta-analysis: the efficacy and safety of direct-acting antivirals in children and adolescents with chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2020;52(7):1125\u201333.","journal-title":"Aliment Pharmacol Ther"},{"issue":"15","key":"1510_CR11","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","volume":"377","author":"E Gane","year":"2017","unstructured":"Gane E, Lawitz E, Pugatch D, et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med. 2017;377(15):1448\u201355.","journal-title":"N Engl J Med"},{"issue":"5","key":"1510_CR12","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/cen.14660","volume":"96","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Xie W, Zheng C, et al. Hypoglycemia associated with direct-acting anti-hepatitis C virus drugs: an epidemiologic surveillance study of the FDA adverse event reporting system (FAERS). Clin Endocrinol (Oxf). 2022;96(5):690\u201397.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1510_CR13","doi-asserted-by":"crossref","unstructured":"Sakaeda T, Tamon A, Kadoyama K, et al. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10(7):796\u2013803.","DOI":"10.7150\/ijms.6048"},{"issue":"9","key":"1510_CR14","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s40264-021-01091-x","volume":"44","author":"E Rocca","year":"2021","unstructured":"Rocca E, Gauffin O, Savage R, et al. Remdesivir in the COVID-19 pandemic: an analysis of spontaneous reports in VigiBase during 2020. Drug Saf. 2021;44(9):987\u201398.","journal-title":"Drug Saf"},{"key":"1510_CR15","doi-asserted-by":"crossref","unstructured":"De Monte A, Courjon J, Anty R, et al. Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge. J Clin Virol. 2016;78:27\u201330.","DOI":"10.1016\/j.jcv.2016.02.026"},{"issue":"7","key":"1510_CR16","doi-asserted-by":"publisher","first-page":"892","DOI":"10.7150\/ijms.43079","volume":"17","author":"H Zeng","year":"2020","unstructured":"Zeng H, Li L, Hou Z, et al. Direct-acting antiviral in the treatment of chronic hepatitis C: bonuses and challenges. Int J Med Sci. 2020;17(7):892\u2013902.","journal-title":"Int J Med Sci"},{"issue":"9","key":"1510_CR17","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1007\/s12325-019-01012-6","volume":"36","author":"TM Welzel","year":"2019","unstructured":"Welzel TM, Yang M, Sajeev G, et al. Assessing patient preferences for treatment decisions for new direct acting antiviral (daa) therapies for chronic hepatitis C Virus Infections. Adv Ther. 2019;36(9):2475\u201386.","journal-title":"Adv Ther"},{"issue":"sup2","key":"1510_CR18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/14740338.2016.1221396","volume":"15","author":"C Scavone","year":"2016","unstructured":"Scavone C, Sportiello L, Rafaniello C, et al. New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs). Expert Opin Drug Saf. 2016;15(sup2):85\u2013100.","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"1510_CR19","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jhep.2018.11.011","volume":"70","author":"R D\u2019Ambrosio","year":"2019","unstructured":"D\u2019Ambrosio R, Pasulo L, Puoti M, et al. Real-world effectiveness and safety of glecaprevir\/pibrentasvir in 723 patients with chronic hepatitis C. J Hepatol. 2019;70(3):379\u201387.","journal-title":"J Hepatol"},{"issue":"5","key":"1510_CR20","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/jamainternmed.2019.7087","volume":"180","author":"RD Savage","year":"2020","unstructured":"Savage RD, Visentin JD, Bronskill SE, et al. Evaluation of a common prescribing cascade of calcium channel blockers and diuretics in older adults with hypertension. JAMA Intern Med. 2020;180(5):643\u201351.","journal-title":"JAMA Intern Med"},{"issue":"1","key":"1510_CR21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2165\/00002018-200022010-00005","volume":"22","author":"O Chassany","year":"2000","unstructured":"Chassany O, Michaux A, Bergmann JF. Drug-induced diarrhoea. Drug Saf. 2000;22(1):53\u201372.","journal-title":"Drug Saf"},{"issue":"3","key":"1510_CR22","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/apt.15586","volume":"51","author":"AM Moon","year":"2020","unstructured":"Moon AM, Green PK, Rockey DC, et al. Hepatitis C eradication with direct-acting anti-virals reduces the risk of variceal bleeding. Aliment Pharmacol Ther. 2020;51(3):364\u201373.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"1510_CR23","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/jvh.12645","volume":"24","author":"E Lawitz","year":"2017","unstructured":"Lawitz E, Poordad F, Gutierrez JA, et al. Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus-infected patients with decompensated liver disease. J Viral Hepat. 2017;24(4):287\u201394.","journal-title":"J Viral Hepat"},{"issue":"5","key":"1510_CR24","doi-asserted-by":"publisher","first-page":"e13345","DOI":"10.1111\/tid.13345","volume":"22","author":"G Pietrosi","year":"2020","unstructured":"Pietrosi G, Russelli G, Barbera F, et al. Direct-acting antivirals ability to clear intestinal HCV-RNA in liver transplant patients. Transpl Infect Dis. 2020;22(5):e13345.","journal-title":"Transpl Infect Dis"},{"issue":"3","key":"1510_CR25","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1002\/hep.26546","volume":"59","author":"V Isakov","year":"2014","unstructured":"Isakov V, Morozov S, Valeyrie-Allanore L. Unusual oral mucosa damage during telaprevir treatment of chronic hepatitis C. Hepatology. 2014;59(3):1209\u201310.","journal-title":"Hepatology"},{"issue":"11\u201312","key":"1510_CR26","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1111\/apt.15004","volume":"48","author":"FR Ponziani","year":"2018","unstructured":"Ponziani FR, Putignani L, Paroni Sterbini F, et al. Influence of hepatitis C virus eradication with direct-acting antivirals on the gut microbiota in patients with cirrhosis. Aliment Pharmacol Ther. 2018;48(11\u201312):1301\u201311.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"1510_CR27","doi-asserted-by":"publisher","first-page":"23568","DOI":"10.1038\/s41598-021-03009-0","volume":"11","author":"T Honda","year":"2021","unstructured":"Honda T, Ishigami M, Yamamoto K, et al. Changes in the gut microbiota after hepatitis C virus eradication. Sci Rep. 2021;11(1):23568.","journal-title":"Sci Rep"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-022-01510-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-022-01510-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-022-01510-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T18:44:16Z","timestamp":1701369856000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-022-01510-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,12]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1510"],"URL":"https:\/\/doi.org\/10.1007\/s11096-022-01510-8","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"type":"print","value":"2210-7703"},{"type":"electronic","value":"2210-7711"}],"subject":[],"published":{"date-parts":[[2022,11,12]]},"assertion":[{"value":"30 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}